Advertisement

Topics

Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval

21:18 EDT 18 Oct 2016 | SCRIP

Genentech’s PD-L1 inhibitor Tecentriq could steal market share from the PD-1 inhibitors Opdivo and Keytruda in its new indication, but...

      

Related Stories

 

Original Article: Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval

NEXT ARTICLE

More From BioPortfolio on "Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval"

Quick Search
Advertisement